EU Agency Recommends Kizfizo for Brain Tumors
The EMA committee backed an oral suspension treatment for adults and children diagnosed with malignant brain tumors.
Updated on Oct. 21, 2026 in Cancer
In October 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for the oral suspension Kizfizo. This medication is intended for adults with newly diagnosed glioblastoma and patients aged 1 year or older with recurrent or progressive malignant glioma.
Why it matters
The recommendation, supported by clinical evidence and bioequivalence data, expands treatment options for patients facing severe brain cancers. It provides an alternative formulation for patients who may struggle with existing capsule options.
The pivotal phase 3 trial enrolled 573 patients, showing a hazard ratio for death of 0.63. Grade 3 or 4 hematologic toxicity was observed in 7% of trial participants.
The players
European Medicines Agency
The European Medicines Agency is a decentralized agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
European Commission
The European Commission is the executive branch of the European Union responsible for proposing legislation and implementing decisions regarding marketing authorizations.
The details
Kizfizo uses the active substance temozolomide, which functions by damaging tumor cell DNA and preventing repair to trigger cell death. The recommendation covers a 40 mg/mL oral suspension, building on the therapeutic foundation established by the original Temodal capsule authorization.
Timeline
January 26, 1999: The Temodal capsule formulation was first authorized in the EU.
August 22, 2025: Kizfizo was granted orphan medicinal product designation for glioma.
October 2026: The CHMP issued its recommendation for the oral suspension.
Health Landscape
The development of Kizfizo follows the European Union orphan medicinal product designation protocols designed to incentivize research for rare conditions. This recommendation marks a significant step in providing specialized formulations for brain cancer patients.
Patients and caregivers may soon have access to a new liquid formulation of temozolomide, potentially simplifying administration for those who have difficulty swallowing capsules. This regulatory step confirms that the treatment met specific safety and efficacy benchmarks in large-scale clinical trials.
The takeaway
This development highlights the ongoing evolution of therapeutic options for glioblastoma patients. Patients should consult their oncologists regarding whether this new oral suspension formulation is appropriate for their specific treatment plan once authorized.
What happens next
The European Commission will now review the CHMP recommendation to determine whether to grant formal marketing authorization for the Kizfizo oral suspension.
Further reading
Find more updates on ongoing research and drug approvals in the Cancer section.
